Chinese diabetes market worth $2.2 billion, with over 50% accounted for by insulin

24 January 2013

Demand within the Chinese insulin market has grown at a fast pace in the past decade. Over the next five years, both production and demand will continue to grow, according to a new report added to the offering of companiesandmarkets.com.

China is the country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated 13.8 billion renminbi ($2.22 billion), of which, insulin medicines comprising recombinant human insulin and insulin analog accounted for 52.8%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Company News Directory



Companies featured in this story

More ones to watch >






Company Spotlight



More Features in Pharmaceutical